Objectives of MPN&MPNr-EuroNet
The main objectives of MPN&MPNr-EuroNet are:
1.To foster, formalize and support collaborationsbetween European MPN expertsto optimize and standardize the molecular diagnosis of MPNs,congenital erythrocytosis and hereditary thrombocytosis(MPN-related diseases or MPNr) in Europe.
2.To optimize and standardize the molecular detection and quantification of the most frequent mutations in MPNs:theJAK2V617Fmutation, JAK2 exon 12 mutations,MPLW515K/L mutations, and CALR mutations.
3.To organize and centralize the investigation of rare mutations in the HIF2A, PHD2, VHL, EPOR, MPL, JAK2and THPOgenes, for the diagnosis of congenital erythrocytosis and hereditary thrombocytosis.
4.To foster research and innovation in the field of MPNs and related hereditary diseases.
MPN&MPNr-EuroNet 32participating countries (in bright blueon the mapbelow)
Austria, Belgium,Bosnia and Herzegovina,Bulgaria, Canada, Croatia, The Czech Republic, Denmark, France, Germany, Greece, Hungary, India, Ireland, Israel, Italy, The Republic of Macedonia, The Netherlands, Norway, Poland, Portugal, Romania, Russia, The Republic of Serbia, Spain,Sweden, Switzerland, Slovakia, Slovenia, Turkey, The United Kingdom, USA.
New members are invited to join and participate in MPN&MPNr-EuroNetworking groups. To register as new member, please click on“To become a member” on the Home page, then follow instructions.